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Introduction
Hemophilia A and B are inherited bleeding disorders due to a X-linked genetic deficiency in clotting factor 
VIII (FVIII) or FIX, respectively. Patients with severe hemophilia (factor levels < 1%) experience frequent 
joint bleeds starting at an early age when not controlled with prophylactic clotting factor replacement ther-
apy (1–3). The frequent exposure of  the joint to blood causes the development of  hemophilic arthropathy 
(HA), a debilitating and irreversible condition that often requires joint replacements at early ages (4). Today’s 
focus on managing acute bleeds in hemophilia and optimizing prophylactic treatment has significantly 
reduced the number of  life-threatening bleeds and delayed the early onset of  HA (1). However, HA contin-
ues to develop later in life, despite prophylaxis, suggesting that breakthrough and/or subclinical bleeding in 
the joints induce pathological soft tissue and osteochondral changes that accumulate over time, causing joint 
deformities and HA (5–7). Indeed, a few bleeds in rapid succession suffice to form target joints (i.e., joints 
with a predisposition to chronic synovial inflammation, persistent bleeding, and at high risk of  developing 
HA; ref. 8). The etiology of  target joint formation and persistent joint bleeding despite clotting factor treat-
ment is multifaceted, as is the pathology of  HA, and remains incompletely understood (4).
One distinctive pathophysiological manifestation of  hemophilic joints associated with bleeding is the 
induction of  excessive and abnormal vascular remodeling (9). Featuring progressive vascular wall remodeling 
Excessive vascular remodeling is characteristic of hemophilic arthropathy (HA) and may contribute 
to joint bleeding and the progression of HA. Mechanisms for pathological vascular remodeling 
after hemophilic joint bleeding are unknown. In hemophilia, activation of thrombin-activatable 
fibrinolysis inhibitor (TAFI) is impaired, which contributes to joint bleeding and may also underlie 
the aberrant vascular remodeling. Here, hemophilia A (factor VIII–deficient; FVIII-deficient) mice 
or TAFI-deficient mice with transient (antibody-induced) hemophilia A were used to determine the 
role of FVIII and TAFI in vascular remodeling after joint bleeding. Excessive vascular remodeling 
and vessel enlargement persisted in FVIII-deficient and TAFI-deficient  mice, but not in transient 
hemophilia WT mice, after similar joint bleeding. TAFI-overexpression in FVIII-deficient mice 
prevented abnormal vessel enlargement and vascular leakage. Age-related vascular changes were 
observed with FVIII or TAFI deficiency and correlated positively with bleeding severity after injury, 
supporting increased vascularity as a major contributor to joint bleeding. Antibody-mediated 
inhibition of uPA also prevented abnormal vascular remodeling, suggesting that TAFI’s protective 
effects include inhibition of uPA-mediated plasminogen activation. In conclusion, the functional 
TAFI deficiency in hemophilia drives maladaptive vascular remodeling in the joints after bleeding. 
These mechanistic insights allow targeted development of potentially new strategies to normalize 
vascularity and control rebleeding in HA.
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with vessel lumen enlargement, these enlarged, tortuous vessels in HA appear fragile and prone to rupture, 
as shown by ample clinical evidence (10–14). Furthermore, association of  high synovial power Doppler (PD) 
signals, a measure of  abnormal microvascular flow and increased vascularity, with subclinical or overt joint 
bleeding in adult patients with hemophilia support the link between vascular changes in the joint and suscep-
tibility to bleeding (9, 11, 15). Normal synovium contains a dense network of  fenestrated blood microvessels 
but is relatively devoid of  larger vasculature. It is conceivable that the presence of  enlarged and possibly 
dysfunctional synovial vascularity contributes to joint bleeding in hemophilia, which in some cases cannot 
be controlled by clotting factor replacement alone, requiring surgical intervention to embolize the vessels and 
stop the bleeding (10, 14, 16–18).
The driving forces for the abnormal growth of  these blood vessels and pathogenic vascular remodeling 
are largely undefined. Neovascularization after joint bleeding is induced by the combination of  hypoxia 
due to synovial hyperproliferation and the expression of  proto-oncogenes and proinflammatory cytokines 
in response to exposure of  the synovium to toxic hemoglobin-derived iron and iron derivatives (4, 19–22). 
Why this neovascular response results in pathogenic vascular remodeling in hemophilia remains undeter-
mined. Excessive vascular remodeling is characteristic of  HA, as it is not observed to the same extent in 
rheumatoid and osteo-arthritis (9, 11). The less conspicuous vascular remodeling in the other arthritides 
indicates that mechanisms other than inflammation- and/or degeneration-driven processes are involved in 
the aberrant hypervascular response in HA, and that most likely the underlying FVIII or FIX deficiency is 
driving the excessive vascular remodeling. The major consequence of  FVIII or FIX deficiency is severely 
impaired thrombin generation, which affects multiple pathways beyond hemostasis.
One important protein, potentially affecting vascular remodeling in the hemophilic joint, is thrombin-ac-
tivatable fibrinolysis inhibitor (TAFI, also known as procarboxypeptidase U or plasma procarboxypeptidase 
B, gene CPB2). TAFI is a circulating proenzyme activated by thrombin or the thrombin-thrombomodulin 
complex (23, 24), and the activation of  TAFI is particularly impaired in hemophilia, as shown in hemophilia 
plasma in vitro (25–27) and in FVIII-gene deficient (FVIII-KO) mice after joint injury in vivo (28). Activated 
TAFI (TAFIa) is a basic carboxypeptidase that removes C-terminal Lys or Arg from specific proteins and 
peptides, resulting generally in their attenuated bioactivity (29, 30). Loss of  TAFIa activity in hemophilia 
was recently found to promote joint bleeding due to unopposed uPA-mediated activation of  plasminogen 
(28), which is normally attenuated by TAFIa due to the removal of  C-terminal Lys from partially degraded 
fibrin (31, 32). In addition, TAFIa has antiangiogenic effects on endothelial cells (33), reduces migration 
and invasion of  breast cancer cells (34, 35), and attenuates the formation of  abdominal aorta aneurysms in 
vivo (36), which was ascribed to its ability to reduce extracellular matrix degradation by suppressing plasmin 
formation. TAFIa also provides protective antiinflammatory effects in various mouse models of  arthritis by 
reducing synovitis and cartilage destruction, and this primarily involves inactivation of  the complement ana-
phylatoxins C3a and C5a, and of  thrombin-cleaved osteopontin by removal of  their C-terminal Arg (37–40).
Thus, based on the defective activation of  TAFI in hemophilia that contributes to joint bleeding and 
TAFI’s protective effects in other arthritis models, we hypothesize that the loss of  TAFIa activity in hemo-
philia provides a disease-promoting role in HA by augmenting the excessive vascular remodeling, thereby 
posing a serious risk for recurrent joint bleeding and development of  HA. Here, we used WT and TAFI-
KO mice with transient (antibody-induced) hemophilia A and congenital hemophilia A (FVIII-KO) mice 
to discern normal from abnormal long-term vascular changes in response to joint bleeding. This approach 
permits the identification of  how FVIII deficiency gives rise to the abnormal vascular responses after joint 
bleeding in hemophilia.
Results
Extensive vascular abnormalities are present in the synovium of  patients with HA. The synovial vascularity of  nor-
mal human knee joints is characterized by small CD31+ vessels in the sublining layer adjacent to the synovial 
layer (Figure 1, A–C) that provides nutrients to the synovial fluid and avascular cartilage. Synovium from 
patients with HA is hyperplastic and has very different synovial vascularity, with a high density of  abnor-
mally enlarged blood vessels with distorted vascular walls throughout the different synovial layers (Figure 
1, D–F). A significant subset of  the abnormally enlarged CD31+ vessels showed excessive perivascular cell 
staining for α-smooth muscle actin (αSMA) (Figure 1, D–F), indicative of  a maladaptive vascular remodel-
ing response (9). While total vessel count (Figure 1G) and average vessel diameter (Figure 1H) were similar 
in HA samples compared with normal controls, the vessel count of  abnormally enlarged vessels with a vessel 
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lumen diameter ≥ 20 μm (Figure 1I) or ≥ 40 μm (Figure 1J) and average diameter of  αSMA+, but not αSMA–, 
blood vessels (Figure 1K) were significantly increased in HA samples, indicating that the vessel enlargement 
and vascular wall remodeling are characteristic of  HA. The needle puncture–induced knee injury model in 
FVIII-KO mice was established to capture these characteristic vascular changes of  HA and permits different 
time-dependent intraarticular soft tissue processes caused by bleeding to be distinguished (Supplemental 
Figure 1 and ref. 28; supplemental material available online with this article; https://doi.org/10.1172/jci.
insight.128379DS1). To discriminate normal (WT) responses to joint bleeding from abnormal responses that 
are caused by FVIII deficiency, these different processes are defined here as bleeding, synovial inflammation 
Figure 1. Vascular changes in synovial samples from hemophilia patients with HA. Representative images of synovial samples from 3 normal control 
donors (numbered 1–3; A–C) and from 3 hemophilia patients with HA (numbered 4–6; 2 examples each; D–F) stained for CD31 (red), αSMA (green), and 
nuclei (Hoechst, blue). Arrowheads indicate synovial surface typically comprising 2–3 cell layers in control samples with a high density of small CD31+αSMA– 
and CD31+αSMA+ vessels in the sublining. In HA synovial samples, abnormally enlarged vessels reside in multiple synovial layers with excessive (αSMA+) 
perivascular remodeling. Original magnification 20×. Scale bar: 100 μm. (G–K) Quantification of 5–7 high-power fields (HPF) per donor and 3 donors per 
condition (median; counts derived from different HPF of the same donor are color coded blue, black, and red). (G) Total vessel count, (H) average vessel 
diameter (μm), (I) vessel count with diameter ≥ 20 μm, (J) vessel count with diameter ≥40 μm, and (K) average vessel diameter (μm) of CD31+αSMA– and 
CD31+αSMA+ count of vessels per HPF. Data were analyzed using 2-tailed, unpaired Mann-Whitney U test (G–K).
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and hyperplasia, neovascularization, and vascular remodeling. While HA in humans progresses as the result 
of  many joint bleeds over time, the FVIII-KO mouse mimics the human joint histopathological changes after 
a single severe joint bleed with regard to maladaptive vascular remodeling (Supplemental Figure 2).
WT mice with transient hemophilia A display synovial hyperplasia and neovascularization after joint bleeding. 
FVIII-KO (Figure 2A) and WT control mice (Figure 2B) were used to study the driving forces responsible 
for the excessive vascular remodeling in hemophilia after joint bleeding. Injury-induced joint bleeding in 
WT mice was achieved by transient antibody-mediated inhibition of  FVIII alone, which induced less than 
hemophilia-like bleeding volumes, or by the inhibition of  both FVIII and TAFI to induce hemophilia-like 
bleeding volumes (Figure 2B and ref. 28). Antibody-induced abrogation of  hemostasis was transient due to 
clearances of  the antibodies in < 5 days (anti-FVIII [ref. 28]; anti-TAFI, Supplemental Figure 3) and per-
mitted the assessment of  the effects of  bleeding volume and the presence of  FVIII during different stages 
after injury on vascular changes in the joint. The FVIII-KO mouse on the BALB/c genetic background 
does not bleed spontaneously (41, 42); accordingly, hematocrit (Hct) (Figure 2C) and joint vascularity at 
baseline were similar to those observed in WT mice (total vessel count of  42 ± 3 in FVIII-KO mice versus 
43 ± 9 in WT mice; Figure 2, D and E), indicating that FVIII deficiency does not induce developmental 
Figure 2. WT mice with transient hemophilia A are protected against excessive vascular remodeling after joint bleeding. (A) Schematic of an estab-
lished joint injury model and bleeding-induced vascular changes in BALB/c FVIII-KO mice (9) with synovial neovascularization normalizing gradually, 
while vascular remodeling into enlarged and distorted vessels progresses. (B) Schematic of the joint injury model in WT mice with transient hemophilia 
A. BALB/c WT mice were administered an inhibitory anti-FVIII antibody alone (WT-inhibitor; WTINH) or together with an anti-TAFI antibody (WT–inhib-
itor plus; WTINH+). After antibody clearance, vascular changes in WT mice were compared at week 2 (W2) and W4 with those in FVIII-KO mice. Asterisk 
indicates time of joint injury at day 0 (D0). Hematocrit (Hct) was determined at D2 after injury to assess joint bleeding severity. (C) Hct at baseline (BL; n = 
5) and D2 in FVIII-KO, WTINH, or WTINH+ mice (n = 12–16). Joint bleeding was inferred from a postinjury Hct drop. (D and E) Total vessel count in medial knee 
joint sections at baseline and after knee injury in FVIII-KO mice (n = 6–11) (D), WTINH mice (E), and WTINH+ mice (n = 5–7) (E). (F) Synovial proliferation (Krenn 
score; n = 5–6) at BL and W2 after injury in FVIII-KO, WTINH, and WTINH+ mice. (G) Large vessel count (with diameter ≥ 20 μm) in medial knee joint sections 
at BL, W2, and W4 after injury in FVIII-KO, WTINH, and WTINH+ mice (n = 5–11). (H) Representative examples of αSMA staining. Scale bar: 100 μm. T, tibia; M, 
meniscus; F, femur. (I) Quantification of the αSMA signal (n = 7–8) in WTINH+ or FVIII-KO mice at BL and at W4 after injury. Each point represents an individ-
ual mouse. Data are presented as mean ± SD and were analyzed using 1-way ANOVA with Tukey’s multiple comparisons test (C, D, G, and I), Kruskal-Wallis 
with Dunn’s multiple comparisons test (F) or Student’s 2-tailed, unpaired t test (E). *P < 0.05; **P < 0.01; ***P < 0.001; ****P < 0.0001.
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or spontaneous vascular abnormalities in these mice. After joint injury in the FVIII-KO mouse, excessive 
bleeding — as shown by a marked drop in Hct at day 2 (D2) after injury (Figure 2C) — caused the for-
mation of  an intra- and periarticular hematoma (Supplemental Figure 1). Joint bleeding in the FVIII-KO 
mouse induced synovial hyperplasia (Figure 2F) and excessive neovascularization (Figure 2D) that was 
more pronounced at week 2 (W2) than W4. WT mice subjected to transient hemophilia A by injection of  
an inhibitory anti-FVIII antibody (WT mouse with inhibitor, WTINH; Figure 2B) developed moderate syno-
vial hyperplasia (Figure 2F) and neovascularization (Figure 2E) at W2 and W4, although only minimal 
joint bleeding was observed in the presence of  the anti-FVIII antibody (some bleeding did occur [ref. 28] 
but not sufficient to induce a decreased D2 Hct) (Figure 2C). In contrast, WT mice without injection of  the 
anti-FVIII antibody subjected to a joint injury did not bleed and did not develop neovascularization or soft 
tissue hyperplasia (Supplemental Figure 4). Therefore, synovial hyperplasia and the neovascular response 
develop in WT mice with transient hemophilia A at very small bleeding volumes that are not seen in hemo-
statically competent WT mice after injury.
WT mice with transient hemophilia A are protected against excessive vascular remodeling after joint bleeding. The 
distinctive feature of  the vascular changes in hemophilia after joint bleeding is the aberrant vascular remod-
eling that is characterized by the formation of  large, irregularly-shaped vessels often (partially) covered by 
a thick layer of  αSMA+ pericytes and vascular smooth muscle cells (Figure 1). However, WTINH mice did 
not show a significant increase in abnormally large blood vessels (≥20 μm) that is typically observed in the 
FVIII-KO mice at W2 or W4 (Figure 2G). The minimal joint bleeding in WTINH mice is due to residual acti-
vation of  TAFI (28). When WT mice were administered an inhibitory anti-TAFI antibody, MA-RT36A3F5, 
in combination with the anti-FVIII antibody (WT mouse with anti-FVIII plus anti-TAFI inhibitor, WTINH+; 
Figure 2B), joint bleeding was quantitatively similar to FVIII-KO mice (Hct at D2, 24.5% ± 7% for WTINH+ 
mice versus 26.5% ± 9% for FVIII-KO mice; Figure 2C). Similar joint vascularity patterns were observed 
in WTINH and WTINH+ mice after injury, independently of  the different joint bleed volumes (Figure 2, E and 
G). Moreover, exposure to blood in the WT joints resulted in an inflammatory and angiogenic response, as 
shown by soft tissue hyperplasia (Figure 2F and Supplemental Figure 5) and an increased total vessel count 
at W2 (Figure 2F), although to a lesser extent than observed in FVIII-KO mice. In stark contrast to FVIII-
KO mice, WTINH+ mice did not develop such enlarged vascular structures (Figure 2G and Supplemental 
Figure 6), despite their similar joint bleed volumes. Although WTINH+ mice showed an increase in the num-
ber of  αSMA+ smaller vessels, the large irregularly shaped αSMA+ vessels typical in FVIII-KO mice were 
notably diminished (Figure 2, H and I). Thus, abnormal vessel enlargement and vascular remodeling were 
almost absent in WTINH+ mice and present with FVIII deficiency, defining a prominent role of  FVIII and/or 
FVIII-dependent downstream factors beyond initial hemostasis to arrest bleeding.
TAFI deficiency results in spontaneously increased joint vascularity with aging. Ultrasound PD has been vali-
dated to measure aberrantly increased blood flow in response to joint bleeding in patients with hemophilia 
(9, 11). In FVIII-KO mice, PD signals increase after joint injury (Supplemental Figure 7) and correlate with 
vessel diameter (9, 15, 43). To test our hypothesis that TAFI deficiency may be the underlying cause of  the 
prolonged vascular dysfunction in hemophilia after bleeding, the joint vascularity of  uninjured TAFI-KO 
mice was characterized by PD. At baseline, a subset of  skeletally mature TAFI-KO mice (3–4 months of  
age) exhibited spontaneously increased PD signals when compared with age-matched WT control mice 
(Figure 3, A and B). In contrast, FVIII-KO mice had normal PD signals at baseline (Figure 3, A and B) that 
corresponded to their intrinsically low baseline vascularity shown by histology (Figure 2, D and G). Because 
HA is most common in the adult hemophilia population, an aging study was conducted in mice to better 
understand the effects of  TAFI and FVIII deficiency on age-related spontaneous changes in joint vascularity 
(Figure 3A). In general, the joint vascularity, measured by PD imaging, increased with aging in WT controls 
(C57Bl/6J [TAFI-KO background] and BALB/c [FVIII-KO background]) and plateaued at 8–10 months 
of  age (Figure 3B). PD signals also increased with age in FVIII-KO mice, but in contrast to WT mice, PD 
signals did not plateau at 8–10 months, continuing to increase with age (Figure 3B) and showing a greater 
abundance of  high-flow areas at 18 months (Figure 3C). In TAFI-KO mice, PD signals were increased in all 
age groups (3, 9, and 18 months), showing markedly altered vascularity patterns (Figure 3D), reminiscent 
of  those seen in FVIII-KO mice after severe joint bleeding. To exclude the possibility that the increased PD 
signals in this TAFI-KO line (44) were due to potential off-target effects as the result of  genetic drift, results 
were confirmed in an independently generated and maintained TAFI-KO strain (45). Indeed, increased PD 
signals were also observed in this TAFI-KO line in both younger (<6 months) and aged (>6 months) mice 
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compared with their respective age-matched WT controls (Supplemental Figure 8). Histological analysis at 
18 months showed an overall increase in joint vascularity in TAFI-KO mice (Figure 4). Vessel count (Fig-
ure 4A) and average diameter (Figure 4B) were higher in 18-month-old TAFI-KO mice. However, vessel 
enlargement expressed as vessel count with a diameter ≥ 40 μm (Figure 4C), and perivascular αSMA signals 
(Figure 4, D and E) were significantly increased in both aged TAFI-KO and FVIII-KO mice, indicating 
enhanced vascular remodeling with aging in these mice and confirming increased vascularity and vessel 
lumen expansion as the cause for the increased PD signals. The augmented age-dependent vessel enlarge-
ment in TAFI-KO mice uncovered a potentially novel physiological role for TAFI in the regulation of  vascu-
larity in weight-bearing joints and extends its protective role in arthritis (39, 40). Furthermore, phenocopying 
of  the hemophilia-related spontaneous vascular changes in the TAFI-KO mouse provides support for our 
hypothesis that defective TAFI activation in hemophilia is responsible for abnormal vascular remodeling.
Maladaptive vascular remodeling with aging increases joint bleeding. Although the link between abnormal vas-
cular remodeling in the joint and susceptibility to joint bleeding in hemophilia is intuitive and based on ample 
clinical experience (9–15), direct experimental evidence is currently lacking. When a very mild joint injury 
was induced in transient hemophilia A TAFI-KO mice (TAFI-KOINH) at 8 months of  age that displayed a 
wide range of  PD signals, a significant correlation was observed between the bleeding severity after joint 
injury and PD signals at baseline before injury (Figure 5A). Stratifying the aged TAFI-KO mice based on PD 
signal at baseline indicated that mice with high PD signals bled significantly more after a very mild joint inju-
ry compared with mice with normal PD signals (Figure 5B). Thus, mice with increased vascular blood flow in 
the joint are predisposed to more severe joint bleeding, providing experimental support for the clinical expe-
rience that dysfunctional vascular remodeling is a major contributor to joint bleeding in hemophilia patients.
TAFI deficiency phenocopies the vascular dysfunction in FVIII-KO mice after joint bleeding. To test whether TAFI 
deficiency causes FVIII-KO–like vascular remodeling after joint bleeding, TAFI-KO mice with a normal base-
line PD signal (less than the mean plus 1× SD) of the baseline PD signal in WT mouse; Supplemental Figure 9) 
were subjected to joint bleeding. Administration of the anti-FVIII antibody (and anti-TAFI antibody) prior to 
Figure 3. Joint blood flow increases spontaneously with aging in TAFI-deficient mice. (A) Analysis of knee joint vascularity at baseline (no injury) by ultra-
sound power Doppler (PD) (pixel2; median ± 95% CI) in BALB/c WT (n = 17–58), BALB/c FVIII-KO (n = 10–61), C57Bl/6J WT (n = 26–41), and C57Bl/6J TAFI-KO 
(n = 25–89) mice at 3–4 months (“3”), 8–10 month (“9”), and 18–22 months (“18”) of age. PD signal was obtained from recording at the medial side of the 
right knee joint. Each point represents an individual mouse. (B) Analysis of age-related increases in PD signal (pixel2; median) in joints of BALB/c FVIII-KO 
mice (n = 10–61) and C57Bl/6J TAFI-KO (n = 25–89) compared with their respective age-matched WT controls (n = 17–58 for BALB/c WT and n = 26–41 for 
C57Bl/6J WT) at 3–4 months (“3”), 8–10 month (“9”), and 18–22 months (“18”). Statistical significance is shown versus age-matched WT control mice. (C 
and D) Representative images of PD recordings at > 18 months for (C) BALB/c FVIII-KO mice and (D) C57Bl/6J TAFI-KO and their respective age-matched 
WT controls. The intensity of vascular flow is pseudocolored from low flow (red) to high flow (yellow) as indicated. Original scaled dimensions are 0.86 cm 
(w) × 0.63 cm (h). Data were analyzed using Kruskal-Wallis with Dunn’s multiple comparisons test. *P < 0.05; **P < 0.01; ***P < 0.001; ****P < 0.0001.
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joint injury (Figure 6A) ensured FVIII-KO–like bleeding (D2 Hct 26.5% ± 9%; Figure 2C) in TAFI-KOINH (D2 
Hct 25.6% ± 4.6%) and C57Bl/6J WTINH+ mice (D2 Hct 29.3% ± 7.8%; Figure 6B). PD signals 4 weeks after 
injury were increased in TAFI-KOINH mice (Figure 6C) and showed markedly altered flow patterns (Figure 
6D), which were similar to those in FVIII-KO mice after injury (Supplemental Figure 7). PD signals 4 weeks 
after injury were not significantly increased in WTINH+ mice compared with preinjury baseline (Figure 6, C and 
D). This suggests that the increased PD signals are caused by TAFI deficiency after the anti-FVIII antibody 
(in TAFI-KOINH and WTINH+ mice) and the anti-TAFI antibody (in WTINH+ mice) have cleared from the cir-
culation (D4–D7 after injury, as determined previously for anti-FVIII antibody [ref. 28]; anti-TAFI antibody 
(Supplemental Figure 3) and that FVIII deficiency at that time is not a prerequisite per se for vascular changes. 
Histological analysis corroborated the PD findings and confirmed that total vessel count (Figure 7A), average 
vessel diameter (Figure 7B), and the number of abnormally enlarged (≥20 μm) vessels (Figure 7C and Supple-
mental Figure 10) were significantly increased in TAFI-KOINH mice compared with WTINH+ mice. Moreover, 
the number of abnormally enlarged vessels in homozygous TAFI-KOINH mice was increased compared with 
that in heterozygous TAFI-KOINH and WTINH+ littermate control mice (Supplemental Figure 11). Absolute 
vessel numbers for vascularity changes in TAFI-KOINH mice (Figure 7, A–C) were similar to those found in 
FVIII-KO mice after injury (Figure 2, D and G). TAFI-KOINH mice also demonstrated significantly increased 
Figure 4. Joint vascularity is increased in aged TAFI-KO mice. Analysis of joint vascularity at baseline (no injury) based on histology of Safranin O 
fast Green–stained sections of BALB/c WT, BALB/c FVIII-KO, C57Bl/6J WT, and C57Bl/6J TAFI-KO mice at 18–22 months of age. Mice with a PD signal 
between the mean ± SD (Figure 3) were selected for histological examination. Each point represents an individual mouse (n = 8–12). (A) Total vessel 
count, (B) average vessel diameter, (C) vessel count with diameter ≥ 40 μm, and (E) quantification of perivascular αSMA signal (pixel2; n = 9–11) of 
BALB/c FVIII-KO mice and C57Bl/6J TAFI-KO at 18–22 months compared with their respective age-matched WT controls. (D) Representative images 
of αSMA staining. Original magnification 40×. Scale bar: 100 μm. Data are represented as mean ± SD and were analyzed using Student’s 2-tailed, 
unpaired t test (A–C and E). *P < 0.05; **P < 0.01.
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synovial hyperplasia (Supplemental Figure 12) and perivascular remodeling, as indicated by an increased 
αSMA signal that was not seen in C57Bl/6J WTINH+ mice (Figure 7, D and E), similar to BALB/c WTINH+ 
mice (Figure 2, H and I). Thus, transient hemophilia A in WT mice did not phenocopy the abnormal vascular 
remodeling response after joint bleeding, as observed in FVIII-KO mice, despite similar joint bleeding volumes 
in the WTINH+ and FVIII-KO mice. TAFI-KO mice with transient hemophilia A (TAFI-KOINH), in contrast, did 
phenocopy the maladaptive vascular remodeling response of the FVIII-KO mice after joint bleeding, as vas-
cularity determined by histological examination was similar between TAFI-KOINH mice and FVIII-KO mice.
TAFI deficiency increases vascular permeability after joint bleeding. Increased vascular permeability and 
edema are key features of  endothelial dysfunction caused by inflammation and/or chronic angiogenesis. 
As previously reported, the vascular permeability of  the joint vasculature markedly increases 2 weeks 
after joint bleeding in the FVIII-KO mouse and normalizes by W4 (15). The increased vascular leakage 
of  Evans blue–albumin in injured joints of  TAFI-KOINH mice was indistinguishable from FVIII-KO mice 
at W2 when compared with the uninjured contralateral joints (Figure 8A), and the ratio of  vascular 
permeability in injured versus contralateral uninjured joints was significantly increased at W2 compared 
with no-injury baseline in both mice and returned to baseline by W4 (Figure 8B). WTINH+ mice did not 
show increased vascular permeability at W2 compared with baseline, consistent with the mild neovascu-
larization reaction in these mice, whereas the vascular leakage of  Evans blue–albumin was significantly 
higher in TAFI-KOINH and FVIII-KO mice compared with their respective WTINH+ controls (Figure 8C). 
Thus, TAFI deficiency phenocopied the aberrant vascular permeability in FVIII deficiency at W2 after 
joint bleeding, suggesting that defective TAFI activation in hemophilia is responsible for the transient 
vascular barrier dysfunction in the joint after bleeding.
A stable TAFI mutant corrects bleeding-induced vascular permeability and abnormal vessel enlargement in 
joints of  FVIII-KO mice. To test whether an increased circulating level of  TAFI in FVIII-KO mice prevents 
bleeding-induced vascular abnormalities in the joints, a human TAFI mutant with a 180-fold extended 
enzymatic half-life (TAFI-CIIYQ; ref. 46) was expressed by hydrodynamic gene delivery (Figure 9A). 
Prior to initiating treatments after injury, mice were randomized according to the Hct determined 2 
days after injury (Figure 9B) to ensure equal bleeding volumes in both groups. The treatment group with 
TAFI-CIIYQ received a hydrodynamic injection that resulted in a plasma TAFI-CIIYQ level of  com-
parable to that of  healthy human plasma 2 days after plasmid DNA injection (Figure 9C). Two weeks 
after injury, TAFI-CIIYQ reduced vascular leakage in FVIII-KO mice from 1.-9 to 1.3-fold (Figure 9D). 
Histological examination 2 weeks after injury showed no differences in total CD31+ vessel counts among 
untreated versus TAFI-CIIYQ–treated FVIII KO mice (Figure 9E); however, expression of  TAFI-CIIYQ 
did cause a significantly reduced formation of  abnormally enlarged vessels (≥20 μm diameter), typical 
Figure 5. Correlation between joint vascularity and injury-induced bleeding. (A) Correlation of joint vascularity in 
C57Bl/6J TAFI-KO mice (8–10 months old; n = 18), as determined by measuring the ultrasound power Doppler (PD) signal 
(pixel2) at baseline versus injury-induced joint bleeding (very mild injury) upon administration of the inhibitory anti-
FVIII antibody. Joint bleeding is inferred from the hematocrit (Hct; %) at day 2 (D2) after injury. (B) Hematocrit at D2 (%; 
mean ± SD) after injury of mice with low (0–50%; n = 9) versus high (50–100%; n = 9) baseline PD signals in C57Bl/6J 
TAFI-KO mice (8–10 months) treated with inhibitory anti-FVIII antibody. Each point represents an individual mouse. 
Correlation was analyzed using the Pearson correlation test (A), and data were analyzed using Student’s 2-tailed, 
unpaired t test (B). *P < 0.05.
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for vascular abnormalities in hemophilia after joint bleeding (Figure 9, F and G). Thus, treatment with 
TAFI-CIIYQ mitigated bleeding-induced vascular defects in hemophilic mouse joints by both preventing 
aberrant vessel enlargement and stabilizing the vascular barrier.
Inhibition of  uPA prevents excessive vascular remodeling in FVIII-KO mice after joint bleeding. To gain insight into 
whether inhibition of  fibrinolysis may contribute to the ability of  TAFIa to protect against the maladaptive 
vascular remodeling response after joint bleeding, the antifibrinolytic drug tranexamic acid (TXA) and the 
inhibitory anti-uPA antibody mU1 (47) were tested for their potential effects on vascular changes after joint 
bleeding in FVIII-KO mice. Treatments were initiated 2 days after joint injury to avoid effects on joint bleed-
ing (28) and to ensure equal bleeding volumes (Figure 10A). As a Lys analog, TXA impedes plasminogen 
binding to partially degraded fibrin and impedes with the fibrin cofactor function in activation of  plasmino-
gen. However, treatment with TXA did not affect the neovascular response (Figure 10B), nor did it correct 
large vessel formation in FVIII-KO mice (Figure 10C). The anti-mouse uPA antibody mU1 that targets uPA’s 
proteolytic activity, but not its binding to uPA receptor (uPAR), also did not affect the neovascular response 
(Figure 10B); however, it did prevent vessel enlargement to a similar degree as TAFI-CIIYQ (Figure 10, C and 
D), indicating that TAFI’s protective effect may at least in part involve the inhibition of  uPA-driven fibrinoly-
sis or pericellular plasmin generation.
Figure 6. TAFI deficiency in mice increases joint blood flow after bleeding. (A) Schematic of the joint injury model comparing C57Bl/6J WT versus TAFI-
KO mice after hemophilic joint bleeding. Mice were administered anti-FVIII antibody alone (TAFI-KO–inhibitor; TAFI-KOINH) or together with an anti-TAFI 
antibody (WT–inhibitor plus; WTINH+). After antibody clearance, vascular blood flow was measured by PD at week 4 (W4) and compared with baseline 
(BL). Asterisk indicates time of joint injury at day 0 (D0). Hematocrit (Hct) was determined at D2 after injury to assess joint bleeding severity. (B) Joint 
bleeding after injury in WTINH+ mice (n = 9) or TAFI-KOINH (n = 10). Joint bleeding was inferred from a postinjury drop in Hct (%; mean ± SD) at D2 compared 
with BL (no-injury reference). Mice with a postinjury Hct below 20% or above 38% were excluded to match the bleeding severity in both groups for anal-
yses. (C) Corresponding analysis of knee joint vascularity at BL and W4 after injury by ultrasound power Doppler (PD) signal (pixel2) in WTINH+ and TAFI-
KOINH mice. Each point represents an individual mouse. (D) Representative PD images (2 examples each) obtained from recordings at the medial side of 
the joint of WTINH+ or TAFI-KOINH at BL or W4 after joint injury. The intensity of vascular flow is pseudocolored from low flow (red) to high flow (yellow) as 
indicated. Original scaled dimensions are 0.86 cm (w) × 0.63 cm (h). Data were analyzed using 1-way ANOVA with Tukey’s multiple comparisons test (B) 
and using Student’s 2-tailed, paired t test (C). ***P < 0.001; ****P < 0.0001.
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Discussion
HA is markedly featured by progressive vascular wall remodeling with vessel enlargement that is associated 
with acute bleeding events in patients with hemophilia (9, 15). While there is consensus that these vascular 
abnormalities are specific to HA (9, 11) and are, thus, caused directly or indirectly by the deficiency of  
FVIII, the mechanism by which FVIII deficiency results in such pronounced vascular defects after joint 
bleeding is unknown.
Here, we used mouse models with genetic and transient hemophilia A to discriminate normal respons-
es to joint bleeding from abnormal responses that are caused by FVIII deficiency. Persistent vascular chang-
es were less pronounced in the transient hemophilia A model in WT mice (WTINH+) where both FVIII and 
TAFI were transiently inhibited to cause joint bleeding quantitatively similar to the FVIII-KO mouse. More 
specifically, WT mice were inherently protected against bleeding-induced excessive vascular remodeling 
and vascular leakage after the inhibitory antibodies cleared the circulation (4–7 days after injury), indicat-
ing that these abnormal vascular changes were associated with FVIII deficiency well after joint bleeding.
Phenocopying of  the hemophilia-specific vascular abnormalities in the TAFI-KOINH mice but not in the 
WTINH+ mice pointed toward a prominent role for TAFI deficiency in the development of  aberrant vascular 
permeability and vascular remodeling after joint injury. Both WTINH+ and TAFI-KOINH mice have similar joint 
bleeding volumes and normalized FVIII functions 1 week after injury (28), but they differ in their ability to 
generate TAFIa when the anti-TAFI antibody has cleared from the circulation. Thus, a prolonged deficiency 
Figure 7. TAFI deficiency in mice underlies excessive vascular remodeling after joint bleeding. Analysis of joint vascularity at baseline (BL; no injury; n = 
4–5), 2 weeks (W2; n = 5), and 4 weeks (W4; n = 8–10) after injury based on histology of Safranin O–fast Green–stained sections of C57Bl/6J WT (treated 
with anti–FVIII antibody and anti-TAFI antibody; WTINH+) or C57Bl/6J TAFI-KO (treated with anti-FVIII antibody; TAFI-KOINH) mice. (A) Total vessel count, (B) 
average vessel diameter (μm), and (C) vessel count with diameter ≥ 20 μm. An independent experiment using littermate controls confirmed the observed 
differences (Supplemental Figure 11). (D) Representative images of perivascular αSMA staining (scale bar: 100 μm; T, tibia; M, meniscus; F, femur) and 
(E) quantification of αSMA signal (pixel2; n = 5–6) in medial knee joint sections of WTINH+ and TAFI-KOINH mice at BL and W4 after joint injury. Each point 
represents an individual mouse. Data are represented as mean ± SD and were analyzed using Student’s 2-tailed, unpaired t test per time point (A–C) and 
1-way ANOVA with Tukey’s multiple comparisons test (E). *P < 0.05; **P < 0.01; ****P < 0.0001.
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of TAFI, but not of  FVIII, was required for the development of  vascular abnormalities after joint injury. 
An indirect mechanism downstream of FVIII deficiency causing vascular abnormalities after joint injury is 
consistent with the notion that TAFI activation is defective in hemophilia plasma in vitro (25, 27) and during 
hemophilic joint bleeding in vivo (28). Moreover, in vitro data show that activation of  TAFI in hemophilia 
plasma is adequately restored by increasing TAFI zymogen levels due to TAFI’s high Km value for activation 
by thrombin (25). Here, overexpression of  a stabilized human TAFI variant, TAFI-CIIYQ (46), prevented 
bleeding-induced vascular permeability and abnormal vessel enlargement in the joint, providing addition-
al support that defective activation of  endogenous TAFI in FVIII-KO mice drives the vascular dysfunction 
induced by bleeding.
To examine the extent to which TAFI’s vascular protective effects in FVIII-KO mice may involve 
inhibition of  plasmin-mediated pericellular proteolysis, the antifibrinolytic agent TXA and the inhibito-
ry mouse uPA antibody, mU1, were tested. Abrogation of  uPA’s proteolytic activity by mU1 prevented 
vessel enlargement and mimicked the effects of  TAFI-CIIYQ, whereas TXA did not. TXA is currently 
used successfully in the clinic to reduce excessive bleeding in orthopedic surgery (48), but TXA has no 
proven effect preventing joint bleeding in patients with hemophilia (49) or in hemophilic mice (28). 
Protection of  the hemophilic joint against excessive vascular remodeling by inhibiting uPA’s proteo-
lytic activity with the anti-uPA antibody mU1, which does not interfere with cellular uPAR binding 
and signaling functions, is consistent with the reported protective effects of  uPA inhibitors in arthritis 
(50). Increased pericellular plasmin formation due to uPA released by endothelial and inflammatory 
cells results in facilitation of  vascular remodeling via enhanced extracellular matrix degradation and 
Figure 8. TAFI deficiency phenocopies the vascular permeability in the joints of FVIII-KO mice after bleeding. (A) 
Representative heatmaps of near-infrared scans showing extravasation of Evans blue–BSA, indicating vascular per-
meability in the injured versus contralateral (uninjured) medial side of the joints (encircled) of FVIII-KO mice and TAFI-
KOINH and their respective WTINH+ controls 2 weeks (W2) after joint bleeding. (B) Time course of the vascular permeabil-
ity (fold increase versus contralateral; mean ± SEM) in the joints of FVIII-KO and TAFI-KOINH mice (full lines) and their 
respective WTINH+ controls (same colored, dashed lines) at baseline W0, W2, or W4 after injury (n = 7–8). Statistical 
significance is shown versus baseline. (C) Vascular permeability (fold increase versus contralateral; mean ± SD) in the 
joints of FVIII-KO and TAFI-KOINH mice and their respective WTINH+ controls 2 weeks after joint injury (n = 8–9). Data 
were analyzed using 1-way ANOVA with Tukey’s multiple comparisons test (B and C). **P < 0.01; ***P < 0.001 versus 
baseline control, unless otherwise indicated.
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augmented vascular cell migration. TAFIa may attenuate uPA-mediated pericellular plasmin formation 
by cleavage of  C-terminal lysines from partially degraded fibrin (51) and plasminogen receptors (35, 
52). Some of  the protective effects of  the anti-uPA antibody may be independent of  TAFI, however, 
as thrombin-mediated inactivation of  single chain uPA may also be reduced in hemophilia (53); this 
cannot be distinguished in the current study. In addition, protection of  the joint against excessive vas-
cular remodeling by TAFI is consistent with other protective functions of  TAFI in arthritic joints that 
involve, at least in part, the inactivation of  osteopontin and the complement anaphylatoxin C5a (38, 40, 
54). Thus, other substrates for TAFIa, left unchecked by the defective activation of  TAFI in hemophilia, 
may also be involved in vascular normalization after joint bleeding, which would extend TAFI’s role in 
hemophilia beyond hemostasis to include inflammation and angiogenesis (28, 55–59).
The development of  vascular abnormalities in the joint was also confirmed in aging TAFI-KO mice 
in 2 independently generated and maintained strains (44, 45). In general, mice exhibited spontaneous-
ly increased vessel diameters with aging that may be a result of  aging-associated chronic and low-grade 
inflammation. Studies focused on aging-related changes to the synovial vasculature are scarce; however, 
less regular arrangement of  synovial vessels and thickening of  the vessel walls with stenosis have been 
described as degenerative changes with aging in human synovium (60, 61). These vascular changes were 
more pronounced in mice with FVIII or TAFI deficiency, indicating that defective TAFI activation may 
result in priming the hemophilic joints into a mild proangiogenic state that is propagated abnormally after 
a hypoxic stimulus, such as caused by bleeding.
Figure 9. Overexpression of a stabilized TAFI variant normalizes vascular dysfunction in hemophilic mice after joint injury. (A) Experimental sche-
matic. Asterisk indicates time of joint injury in FVIII-KO mice at time point day 0 (D0). Hematocrit (Hct) was determined at D2 after injury to assess 
joint bleeding severity. Mice were randomized based on their Hct and received either saline or TAFI-CIIYQ–encoding plasmid by hydrodynamic gene 
delivery. At week 2 (W2) after injury, vascular permeability, total vessel count, and large vessel count were determined. (B) Hct at baseline (BL) and 
D2 after injury of FVIII-KO treated with saline or TAFI-CIIYQ (n = 7–10). Joint bleeding was inferred from a postinjury drop in Hct compared with BL. (C) 
In vivo expression levels (% of normal human plasma [NHP] TAFI level) of circulating TAFI-CIIYQ 2 days after hydrodynamic gene delivery (n = 6) ver-
sus saline injection (n = 3). (D) Vascular permeability (fold increase versus contralateral) in the joints of FVIII-KO mice at BL (n = 8) or W2 after injury 
treated with saline (n = 8) or TAFI-CIIYQ (n = 5). (E and F) Total CD31+ vessel count (E) and large CD31+ vessel count (with diameter ≥ 20 μm) (F) in 
medial knee joint sections per high-power field (HPF) averaged (n = 4–5 HPF) per mouse joint at BL or W2 after injury treated with saline or TAFI-CI-
IYQ (n = 4–6 mice). (G) Representative images of medial joint sections (examples from 2 mice, #1 and #2) of soft tissue at the anterior meniscus (M) 
from FVIII-KO mice W2 after injury stained for CD31 (red), αSMA (green), and nuclei (Hoechst, blue) treated with saline (top) and TAFI-CIIYQ (bottom). 
Open arrowheads indicate CD31+ vessels with a diameter ≥ 20 μm. Original magnification 20×. Scale bar: 100 μm. Data are represented as mean ± SD 
and were analyzed using 1-way ANOVA with Tukey’s multiple comparisons test (B and D–F). **P < 0.01; ***P < 0.001; ****P < 0.0001.
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Synovial inflammation, hypertrophy, and neovascular responses to bleeding were also observed in 
WT mice with transient hemophilia A, albeit milder than in FVIII-KO mice, suggesting that these com-
prise normal responses to injury and blood in the joint and are part of  the repair and regenerative pro-
cesses that precede healing. Many of  these responses were shared between genetic and transient hemo-
philia mice, but ultimately, the responses in WT mice diverged from the FVIII-KO–like pathology, such 
that the neovascular response was followed by the eventual pruning and normalization of  blood ves-
sel growth. Although proreparative mechanisms are upregulated in FVIII-KO mice after joint bleeding 
(i.e., increased M2-polarized macrophage response and antiinflammatory cytokines [refs. 15, 62]), the 
response appears to be maladaptive, as evidenced by differential healing propensities between transient 
hemophilia A WT and FVIII-KO mice. These different phenotypes observed in FVIII-KO and WT mice 
point to an important disease-modifying role for the extent of  thrombin generation during the healing 
phase. Although numerous proenzymes are directly or indirectly affected by reduced thrombin genera-
tion that may affect outcome, the defective activation of  TAFI in FVIII-KO mice, causing a functional 
TAFI deficiency, plays a major role in aberrant vascular remodeling in HA.
Another difference between WT mice and FVIII-KO or TAFI-KO mice was the aberrant vascular perme-
ability in the joint at W2 after joint bleeding. Vascular leakage was notably less severe in the WTINH+ mice and 
TAFI-CIIYQ–expressing FVIII-KO mice compared with FVIII-KO and TAFI-KOINH mice, indicating that the 
excessive permeability was due to TAFI deficiency, regardless of whether FVIII was present (TAFI-KOINH). 
The extent to which vascular permeability in the joint parallels or precedes aberrant vascular remodeling is 
currently not known, but increased synovial blush in the joint is frequently associated with joint bleeding in 
patients with HA (16–18, 63). In addition, the current study demonstrates that aged TAFI-KO mice with spon-
taneous aberrantly remodeled vessels, as indicated by high PD signals in their joints, were prone to more seri-
ous anti-FVIII antibody–induced bleeding compared with mice with normal/low PD signals. Thus, these data 
provide experimental evidence for the clinical association that abnormal flow patterns due to excessive vascular 
remodeling and the formation of disorganized fragile blood vessels in the soft tissue are associated with joint 
bleeding in patients with hemophilia.
In summary, this study identified defective TAFI activation in hemophilia A as an instigator of  the 
development of  pathologically enlarged and abnormally remodeled blood vessels in the joint after injury. 
The notion that TAFI deficiency is sufficient to phenocopy the abnormal vascular remodeling after joint 
injury even in the presence of  FVIII provides the missing mechanistic link between hemophilic joint bleed-
ing and the abnormal vascular leakage and remodeling in HA. These mechanistic insights will help direct 
targeted studies on the development of  vascular normalization approaches in HA and suggest the evaluation 
Figure 10. Inhibition of uPA prevents vascular remodeling in hemophilic mice after joint injury. (A) Hct at baseline (BL) and D2 after injury of FVIII-KO 
treated with saline, TXA, or mU1 (n = 4–6). Joint bleeding was inferred from a postinjury drop in Hct compared with BL. (B and C) Total CD31+ vessel count 
(B) and large CD31+ vessel count (with diameter ≥ 20 μm) (C) in medial knee joint sections per high-power field (HPF) averaged (n = 4–5 HPF) per mouse 
joint at BL or W2 after injury treated with saline or TXA or mU1 (n = 4–6). (D) Representative image of medial joint sections of soft tissue at the anterior 
meniscus (M) from FVIII-KO mice W2 after injury stained for CD31 (red), αSMA (green), and nuclei (Hoechst, blue) treated with TXA (top) and mU1 (bot-
tom). Open arrowheads indicate CD31+ vessels with a diameter ≥ 20 μm. Original magnification 20×. Scale bar: 100 μm. Data are represented as mean ± SD 
and were analyzed using 1-way ANOVA with Tukey’s multiple comparisons test (A–C). *P < 0.05; ***P < 0.001; ****P < 0.0001.
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of  more aggressive prohemostatic treatment strategies in the period after a joint bleed in patients with hemo-
philia to promote normal TAFI activation and dampen the dysfunctional vascular response.
Methods
Animals. FVIII-KO mice on a BALB/c background (64) were a gift of  David Lillicrap (Queens University, 
Ontario, Canada), and WT-BALB/c were obtained from The Scripps Research Institute internal breed-
ing facility. TAFI-KO mice on a C57Bl/6J background were a gift of  Joost Meijers (Sanquin Research 
Amsterdam, The Netherlands) (44, 45) and were backcrossed 5 generations to C57Bl/6J obtained from 
The Scripps Research Institute internal breeding facility to confirm key findings. A second, independently 
generated TAFI-KO strain on a C57Bl/6J background was maintained at Stanford University School of  
Medicine (45). Skeletally mature mice (age 12–16 weeks) of  both sexes were used for joint injury studies. 
Moist food was provided on the cage floor, and s.c. injections of  buprenorphine (0.1 mg/kg, Buprenex, 
Henry Schein) diluted in 400 μl sterile saline (0.9%, Hospira Inc.) were administered daily after injury to 
provide pain relief  and fluids until the mice were mobile.
Joint injury model. Injury in the mouse right knee joint was induced by subpatellar punctures using a 
30G needle as described (65). Injury-induced bleeding was determined by Hct 2 days after the injury as 
described (66). A severe injury model was used, consisting of  5 consecutive pokes, to obtain similar bleed-
ing in acquired hemophilia WT mice as in FVIII-KO mice. A very mild injury consisting of  a single poke 
was used to examine the contribution of  the baseline vascularity on subsequent joint bleeding.
Animal treatments. Two hours before joint injury, mice were injected retro-orbitally with the inhibitory 
anti-FVIII antibody (0.25 mg/kg, #GMA-8015, clone 4A4, Green Mountain Antibodies), GMA-8015 (0.25 
mg/kg, Green Mountain Antibodies) (67, 68), and/or the inhibitory anti-TAFI antibody (7.5 mg/kg, clone 
MA-RT36A3F5, provided by Paul Declerck, University of  Leuven, Belgium [refs. 28, 69]), MA-RT36A3F5 
(28, 69), which destabilizes TAFIa in sterile saline (0.9%, Hospira Inc.) to disrupt joint hemostasis. Therapeu-
tic application of  TAFI was achieved by hydrodynamic gene delivery of  a human TAFI mutant, TAFI-CI-
IYQ, with an 180-fold extended activity of  TAFIa (46). The DNA encoding for TAFI-CIIYQ was inserted 
in the pLIVE vector (Mirus Bio), and a volume of  10% of the mouse body weight containing 50 μg plasmid 
DNA in sterile saline (0.9%, Hospira Inc.) was injected in the tail vein within 5 seconds. In vivo expression 
of  TAFI was quantified by an ELISA assay specific to human TAFI (70), with similar reactivity to TAFI-CI-
IYQ. Treatment with TXA (4-[aminomethyl]cyclohexane-1-carboxylic acid; Acros Organics) was initiated 
at D2 after injury and given continuously up to 2 weeks in the drinking water at an effective dosage to shut 
down ex vivo tissue-type plasminogen activator–mediated (tPA-mediated) clot lysis (71). Treatment with an 
anti-mouse uPA antbody (clone mU1, generated as described [ref  47]), mU1 was similarly initiated at D2 and 
given twice a week at 60 mg/kg up to 2 weeks (50).
Pharmacokinetics of  the anti-TAFI antibody MA-RT36A3F5. Plasma concentration-time profiles of  anti-
mouse TAFI antibody (clone MA-RT36A3F5, provided by Paul Declerck, University of  Leuven, Belgium) 
were determined in TAFI-KO mice after retro-orbital injection at a dosage of  7.5 mg/kg. Plasma samples 
were prepared by collecting blood from the retro-orbital plexus in 3.8% sodium citrate (Fisher Scientific) 
at 1 minute, 1 hour, 24, 48, 120, 168, 288, and 504 hours, followed by subsequent centrifugation at 5000 g 
for 10 minutes. MA-RT36A3F5 concentration was determined by ELISA coated with recombinant mouse 
TAFI (gift from Paul Declerck, University of  Leuven, Belgium) and developed with goat anti-mouse IgG-
HRP (#31439; Pierce). Endogenous TAFI levels in mice were determined by a sandwich ELISA utilizing 
MA-RT36A3F5 and MA-RT30D8–HRP (gift from Paul Declerck, University of  Leuven, Belgium) (72).
Table 1. Patient characteristics
Donor number in Figure 1 Condition Tissue Sex Age (years)
#1 Normal Medial synovium Male 36
#2 Normal Medial synovium Female 34
#3 Normal Medial synovium Male 16
#4 Severe hemophilia B Medial synovium Male 55
#5 Severe hemophilia A Medial synovium Male 37
#6 Severe hemophilia A Medial synovium Male 73
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Histology. Mouse knee joints were fixed in 10% zinc-buffered formalin (Z-fix, Anatech LTD) for 2 days 
and decalcified in Shandon TBD-2 Decalcifier (ThermoFisher Scientific) for 48–72 hours. Sagittal sections 
(4-μm thick; until anterior and posterior horns of  the medial meniscus appeared as triangles between the 
femoral condyle and tibial plateau) were stained with Safranin O–fast green (Safranin O and fast green 
from Sigma-Aldrich) as described previously (73).
IHC and immunofluorescence. Knee joint sections were deparaffinized, washed, and blocked with Odys-
sey Blocking Buffer (LI-COR) (supplemented with 1% BSA). Primary rabbit polyclonal anti-αSMA anti-
body (1:100; ab5964, Abcam) was applied and incubated overnight at 4°C, followed by Impress reagents 
(Vector Laboratories) and development with VectorRed (Vector Laboratories). The αSMA immunosignal 
was quantified using a Color Threshold macro in ImageJ (NIH) at the anterior and posterior meniscal area 
at 10× magnification, and signals were represented as the sum of  anterior and posterior signals.
For immunofluorescence of  clinical synovial samples, deparaffinized and washed sections were incu-
bated with pepsin solution (Digest-All, Invitrogen) for antigen retrieval, followed by incubation with block-
ing buffer supplemented with 2% donkey serum (Jackson ImmunoResearch Laboratories). Alternatively, 
mouse hindlimb samples were frozen and sectioned on cryofilm using a diamond-coated blade (C.L. Stur-
key) using the Kawamoto method (74). Sections were fixed in acetone (Fisher Scientific) for 5 minutes, 
washed, and blocked in blocking buffer supplemented with 2% donkey serum. Primary goat anti-mouse 
CD31 (with cross reactivity to human CD31; 1:20; AF3628, R&D systems) and rabbit anti-αSMA antibody 
(1:100; ab5964, Abcam) were used and incubated overnight at 4°C, followed by Alexa Fluor 568 Cy3 don-
key anti-goat IgG (#705-165-147, Jackson ImmunoResearch Laboratories) and Alexa Fluor 488 donkey 
anti-rabbit IgG (# 711-545-152, Jackson ImmunoResearch Laboratories).
Histological assessment of  vascularity and inflammation. To evaluate synovial and stromal hyperplasia and vas-
cularity, semiquantitative scoring was performed on Safranin O-fast green–stained joint sections using Valenti-
no (scores 0–9), and Krenn (scores 0–3) scoring systems for the evaluation of synovial and stromal hyperplasia, 
respectively (75, 76). Vascularity was determined as total vessel count per joint, including all synovial and 
stromal tissue between femoral and tibial growth plates on Safranin O-fast green–stained sections or analyzed 
on 4–5 high-power fields (HPF) at 20× magnitude on sections stained for CD31 by immunofluorescence. Indi-
vidual vessel diameters were measured at 40-fold magnification (Safranin O-fast green staining on which only 
blood vessels with a distinguishable vessel wall and lumen or deduced by the presence of RBCs were consid-
ered) or at 20-fold magnification (aided by immunofluorescent staining of CD31 including capillaries with no 
detectable lumen). Vessel diameters were measured in increments of 5 μm by rounding down (e.g., diameters 
between 5–9 μm were considered as 5 μm). For elliptical vessels, the larger diameter was recorded unless it was 
equal to or exceeded the smaller diameter by 2.5-fold. Counting was performed randomized and blinded.
Joint blood flow analysis by ultrasound PD. Joint blood flow was studied using high-resolution musculo-
skeletal ultrasound (MSKUS) with the GE Logiq E model with gray scale (B-mode) and PD, using trans-
ducer frequencies of  8–16 MHz as described previously (9, 15). Experimenter was blinded to the mouse 
identities. Quantification of  PD signal was performed using a macro for Color Thresholding in ImageJ.
Vascular permeability assay. Assessment of  vascular permeability by means of  extravasation of  albu-
min-bound Evans blue dye Evans blue (Sigma-Aldrich) in the mouse knee joints after joint bleeding was per-
formed as described previously (15). Baseline and injured FVIII-deficient mice were injected i.v. with 5 μl/g 
0.1% Evans blue containing 0.8% (w/v) BSA (Sigma-Aldrich) in sterile PBS. Two hours later, transcardial 
perfusion was performed at a flow rate of  56 ml/minute for 4 minutes to ensure adequate hindlimb perfu-
sion, and extravasation of  Evans blue was quantified on the medial and lateral sides of  the harvested knee 
joints, positioned on a 1 mm–thick glass slide, at 700 nm using an Odyssey near-infrared imaging system (4 
mm offset; laser intensity 2.0; LI-COR). Medial and lateral readings were combined to give total raw fluo-
rescence intensity (RFI) and were expressed as the ratio of  right (injured joint) to left (uninjured joint) RFI.
Statistics. The following tests (2-tailed Mann-Whitney U test, Student’s unpaired t test, 1-way ANOVA 
with Tukey’s multiple comparison, and Kruskal-Wallis with Dunn’s multiple comparisons test) as specified 
in the figure legends were used to determine statistical significance. Correlations were analyzed using the 
Pearson correlation test. A P value of  <0.05 was considered statistically significant and was calculated 
using GraphPad Prism (San Diego, CA). Data are expressed as mean ± SD unless noted otherwise.
Study approval. The harvesting of  human synovial tissues at the time of  total knee replacement surgery 
was approved by the Scripps Human Subjects Committee and the University of  California (UCSD, San 
Diego, CA) Human Research Protection Program (HRPP). Subjects provided informed consent prior to 
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their participation in the study. Subject characteristics are summarized in Table 1. All animal protocols 
were approved by the IACUC of  The Scripps Research Institute.
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